| UHC Commercial Medical & Drug | Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Roctavian® (Valoctocogene Roxaparvovec-Rvox) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sacral Nerve Stimulation for Urinary and Fecal Indications – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sensory Integration Therapy and Auditory Integration Training – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Spinal Fusion and Bone Healing Enhancement Products – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Subcutaneous Implantable Naltrexone Pellets – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Surgery for the Prevention and Treatment of Lymphedema – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Surgery of the Foot – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Surgery of the Hand or Wrist – Commercial and Individual Exchange Medical Policy | 2026-01-01 |